Publication: Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™- DEN2) vaccine: Phase I clinical trial for safety and immunogenicity - Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes
4
Issued Date
2006-01-01
Resource Type
ISSN
15548619
15548600
15548600
Other identifier(s)
2-s2.0-33745237160
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Human Vaccines. Vol.2, No.2 (2006), 60-67
Suggested Citation
Farshad Guirakhoo, Scott Kitckener, Dennis Morrison, Remi Forrat, Karen McCarthy, Richard Nichols, Sutee Yoksan, Xiaochu Duan, Thomas H. Ermak, Niranjan Kanesa-Thasan, Philip Bedford, Jean Lang, Marie Jose Quentin-Millet, Thomas P. Monath Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™- DEN2) vaccine: Phase I clinical trial for safety and immunogenicity - Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Human Vaccines. Vol.2, No.2 (2006), 60-67. doi:10.4161/hv.2.2.2555 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/23377
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™- DEN2) vaccine: Phase I clinical trial for safety and immunogenicity - Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes
Other Contributor(s)
Abstract
A randomized double-blind Phase I Trial was conducted to evaluate safety, tolerability, and immunogenicity of a yellow fever (YF)-dengue 2 (DEN2) chimera (ChimeriVax™-DEN2) in comparison to that of YF vaccine (YF-VAX®). Forty-two healthy YF naïve adults randomly received a single dose of either ChimeriVax™-DEN2 (high dose, 5 log plaque forming units [PFU] or low dose, 3 log PFU) or YF-VAX® by the subcutaneous route (SC). To determine the effect of YF preimmunity on the ChimeriVax™-DEN2 vaccine, 14 subjects previously vaccinated against YF received a high dose of ChimeriVax™-DEN2 as an open-label vaccine. Most adverse events were similar to YF-VAX® and of mild to moderate intensity, with no serious side-effects. One hundred percent and 92.3% of YF naïve subjects inoculated with 5.0 and 3.0 log10PFU of ChimeriVax™-DEN2, respectively, seroconverted to wt DEN2 (strain 16681); 92% of subjects inoculated with YF-VAX® seroconverted to YF 17D virus but none of YF naïve subjects inoculated with ChimeriVax-DEN2 seroconverted to YF 17D virus. Low seroconversion rates to heterologous DEN serotypes 1, 3 and 4 were observed in YF naïve subjects inoculated with either ChimeriVax™-DEN2 or YF-VAX®. In contrast, 100% of YF immune subjects inoculated with ChimeriVax™-DEN2 seroconverted to all 4 DEN serotypes. Surprisingly, levels of neutralizing antibodies to DEN 1, 2 and 3 viruses in YF immune subjects persisted after 1 year. These data demonstrated that (1) the safety and immunogenicity profile of the ChimeriVax™-DEN2 vaccine is consistent with that of YF-VAX®, and (2) preimmunity to YF virus does not interfere with ChimeriVax™-DEN2 immunization, but induces a long lasting and cross neutralizing antibody response to all 4 DEN serotypes. The latter observation can have practical implications toward development of a dengue vaccine. ©2006 Landes Bioscience.